AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06185673 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: BB-301: Dose escalation phase 1b cohort 3
Description: BB-301 is composed of an AAV9 capsid, AAV9PL, which delivers the gene of interest, comprised of a recombinant genome encoding a single RNA transcript that produces a codon-optimized, wildtype PABPN1 protein as well as 2 shRNAs directed against the disease-causing mutant PABPN1 gene.~Subjects in cohort 3 in the dose escalation phase of the study will receive a fixed number of IM injections of BB-301 into the respective pharyngeal constrictor muscles on the day of dosing, with a total dose of 5.4e13 vg/subject.
Study NCT06185673 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: BB-301: Dose expansion phase 2a
Description: Subjects in the dose expansion phase of the study will receive a fixed number of IM injections of BB-301 into the respective pharyngeal constrictor muscles on the day of dosing, at the maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D).
Study NCT05969509 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: progressive relaxation exercise
Description: applying progressive relaxation exercise to the experimental group after postoperative cholecystectomy and observing the experimental-control groups
Study NCT06253156 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: virtual reality
Description: It is planned to provide 4 sessions of standard disaster preparedness training to nursing students in the intervention group. After the standard training sessions are completed, nursing students will be shown disaster simulation videos and visuals using virtual reality glasses within the scope of the virtual reality-based disaster preparedness training program.
Study NCT06409312 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Akina Cloud
Description: Akina Cloud is a digital health application that supports the therapeutic training of people with musculoskeletal conditions. It provides two therapeutic training programs for patients, one for each specific indication. Patients have continuous access to these programs through Akina Cloud, allowing them to independently complete nine training sessions without supervision. A minimum of three sessions per week is recommended, but patients have the option to engage in daily sessions if preferred. These therapy programs are based on current treatment guidelines and supported by relevant scientific research. They include customizable physical exercises tailored to individual needs and difficulty levels. Patients receive audio-visual guidance during these exercise sessions to ensure proper execution. Exercise therapy has demonstrated its ability to reduce pain, improve physical function, and enhance the overall quality of life for patients suffering from back pain and hip osteoarthritis.
Study NCT05741255 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Acceptance and Commitment Therapy
Description: type of mindful psychotherapy that helps you stay focused on the present moment and accept thoughts and feelings without judgment. It aims to help you move forward through difficult emotions so you can put your energy into healing instead of dwelling on the negative.
Study NCT05741255 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy
Description: type of mindful psychotherapy that helps you stay focused on the present moment and accept thoughts and feelings without judgment. It aims to help you move forward through difficult emotions so you can put your energy into healing instead of dwelling on the negative.
Study NCT05677490 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05677490 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04847661 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mefloquine as a prophylaxis against SARS-Cov-2 infection in household contacts of COVID 19 confirmed cases
Description: Mefloquine hydrochloride will be given in a dose of 1100-1650 mg, according to body weight (BW), splitted into two to three doses.
Study NCT04847661 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mefloquine as a prophylaxis against SARS-Cov-2 infection in household contacts of COVID 19 confirmed cases
Description: Mefloquine hydrochloride will be given in a dose of 1100-1650 mg, according to body weight (BW), splitted into two to three doses.
Study NCT06349395 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MBSR surgical nursing care
Description: This study delivered an eight-session mindfulness-based stress reduction (MBSR) program online to its intervention group, each lasting about two hours, incorporating daily exercises monitored via phone. The evaluation of MBSR's effectiveness focused on postoperative pain at 6, 12, 18, and 24 hours after surgery and assessed fear of movement before starting arm exercises on the 5th day post-mastectomy. This approach provided a detailed examination of MBSR's role in pain and movement fear management, highlighting its potential as a preoperative care component for breast cancer patients.
Study NCT06063421 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electronic Cigarette (EC)
Description: The intervention consists of the use of an Electronic cigarette device namely the Vaporesso Gen Air 40 Vape Kit. This is a complete kit including the EC device, integrated battery, refillable tank, charging cable, coil replacements and user manual. Three e-liquid flavours will be provided; tobacco, menthol and fruit flavour.
Study NCT06063421 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Replacement Therapy
Description: NRT will be in the form of combination therapy with a transdermal nicotine patch (7, 14, or 21mg) and an oral product: either gum or lozenge in 1, 2, or 4mg strength.
Study NCT04606459 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coronary sinus reducer
Description: The Reducer System comprises the Reducer device (Reducer) pre-mounted on the Reducer Balloon Catheter. The Reducer System is available in one model size. The Reducer is a sterile, single-use, implantable device designed to establish a narrowing in the coronary sinus (CS) and is intended to improve perfusion to ischemic myocardium in the presence of reversible ischemic heart disease to alleviate the symptoms of refractory angina. The device is implanted percutaneously through the right internal jugular vein into the CS. The Reducer is pre-mounted (crimped) on the Reducer Balloon Catheter which, after inflation, causes device expansion and apposition with the vessel wall. The balloon catheter is then deflated and removed from the CS, leaving the device permanently implanted.
Study NCT04606459 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Optimal medical therapy
Description: Guideline-directed medical therapy
Study NCT05020600 — intervention group
Intervention type: DRUG
Intervention: Duloxetine
Description: First-line fibromyalgia treatment
Study NCT05020600 — intervention group
Intervention type: DRUG
Intervention: Pregabalin
Description: First-line fibromyalgia treatment
Study NCT05020600 — intervention group
Intervention type: DRUG
Intervention: Amitriptyline
Description: First-line fibromyalgia treatment
Study NCT04870476 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-delivered treatment: One step at the time
Description: The guided internet treatment program consists of 11 modules (+ 1 module for relatives) activated consecutively over a period of 14 weeks. The content is written psychoeducation, patient videos, audio exercises and exposure exercises. The program is therapist-guided; hence all patients will receive support primarily from a specific therapist during the 14 weeks.
Study NCT05598892 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Training with Robotic Hand Exoskeleton
Description: The intervention consists in Robotic Hand training sessions. Each subject received 16 sessions lasting 60 minutes each and a frequency of 2 sessions per week. The sessions will be applied by an Ocupational Therapist with experience in Robotic training. Robhand exoskeleton (ITAP, Valladolid, Spain) is an exoskeleton-type electromechanical device, which is attached to the patient's hand and provides assistance for performing different types of finger movement rehabilitation therapies. The exoskeleton is composed of five independent subassemblies that are placed on a platform which is located on the back of the hand, with the exception of the thumb subassembly that is mounted on a separated module connected to the hand support platform through a linkage device.
Study NCT04856553 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute effects of handgrip exercise
Description: The participants will be randomized into three sessions, handgrip exercise in the morning, handgrip exercise in the afternoon, and control performed in the morning to analyze the acute effects of handgrip exercise on blood pressure and vascular function at different times of the day. After the morning sessions, ambulatory blood pressure will also be measured for 24 hours.
Study NCT05687084 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Uterine manipulator use
Description: The uterine manipulator will be inserted into the uterus to assist in the procedure of total hysterectomy.
Study NCT05430100 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The effect of usıng breast mılk pacıfıer ın reducıng the paın that occurs durıng orogastrıc tube ınsertıon ın preterm newborns
Description: 5 Minutes before the OGT insertion, the camera recording will be started and the preterm newborn will be given a breast milk pacifier. After the breast milk pacifier in the OGT intervention group is placed in the mouth as a leak from the edge of the given baby's mouth, the baby's esophagus will be placed by advancing from there to the stomach with the swallowing reflex. It will be checked whether the OGT is in the right place. Registration will be stopped after the evaluation period is completed and the baby is provided with comfort. But the recording will continue so that there are no time restrictions for tracking the crying time of the baby who continues to cry during placement. In terms of the reliability of the research results, nothing should be given orally to a preterm newborn at least 30 minutes before the procedure.
Study NCT05430100 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The effect of usıng sucrose pacıfıer ın reducıng the paın that occurs durıng orogastrıc tube ınsertıon ın preterm newborns
Description: The camera recording will be started 5 minutes before the OGT insertion procedure and the newborn will be given a sucrose-sweetened pacifier. After the sucrose-sweetened pacifier in the OGT intervention group is placed in the mouth as a leak from the edge of the given baby's mouth, the baby's esophagus will be placed by advancing from there to the stomach with a swallowing reflex. It will be checked whether the OGT is in the right place. Registration will be stopped after the evaluation period is completed and the baby is provided with comfort. But the recording will be continued so that there are no time restrictions for tracking the crying time of the baby who continues to cry during placement. In terms of the reliability of the research results, nothing should be given orally to a preterm newborn at least 30 minutes before the procedure.
Study NCT05430100 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The effect of usıng pacıfıer ın reducıng the paın that occurs durıng orogastrıc tube ınsertıon ın preterm newborns
Description: The camera recording will be started 5 minutes before the OGT insertion procedure and the newborn will be given a pacifier. After the pacifier in the OGT intervention group is placed in the mouth as a leak from the edge of the given baby's mouth, the baby's swallowing reflex will be placed by moving the esophagus from there to the stomach. It will be checked whether the OGT is in the right place. Registration will be stopped after the evaluation period is completed and the baby is provided with comfort. But the recording will be continued so that there are no time restrictions for tracking the crying time of the baby who continues to cry during placement.
Study NCT04788043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magrolimab
Description: 45 mg/kg with dose escalation starting at 1 mg/kg IV Infusion
Study NCT04788043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg IV infusion
Study NCT04788043 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET/CT
Description: Scan
Study NCT05044156 — intervention group
Intervention type: OTHER
Intervention: salivary sample
Description: salivary sample
Study NCT04854681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2928 Injection
Description: 4 weekly IV infusions (Days 1, 8, 15, and 22) of TQB2928 in each 28-day treatment cycle until unacceptable toxicity, documentation of confirmed progressive disease (PD), or subject withdrawal.
Study NCT05318456 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MoodElite T-4003-1
Description: Participants will be instructed to take two capsules of MoodElite T-4003-1 once daily with water, after dinner without food for 42 days.
Study NCT05318456 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Comparator
Description: Participants will be instructed to take two capsules of comparator once daily with water, after dinner without food for 42 days.
Study NCT05318456 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be instructed to take two capsules of placebo once daily with water, after dinner without food for 42 days.
Study NCT05419089 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robotic surgery
Description: Transoral robotic surgical resection of the tumor with negative intraoperative frozen section margins.
Study NCT06207136 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mediterranean-style diet
Description: Coaching in the intervention diet group will promote higher consumption of healthier foods and cooking oils, while discouraging processed foods.
Study NCT06207136 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mediterranean-style diet
Description: Coaching in the intervention diet group will promote higher consumption of healthier foods and cooking oils, while discouraging processed foods.
Study NCT04638569 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: obturator nerve block
Description: The ultrasound probe will be placed in the middle of the tuberculum pubis and femoral artery, 5-6 cm below the inguinal ligament, and 5 mL of 0.5% bupivacaine will be injected into the anterior and posterior branches of the ON with a needle. In the second group, after the patient is placed in the lithotomy position, 1.5 cm lateral tuberculum pubis and 1.5 cm caudal will be marked and needle entry will be made and 0.5% bupivacaine will be injected with 10 mL. The time elapsed until the first needle insertion and local anesthetic injection is completed will be recorded as the application time.
Study NCT04438174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Processed Amniotic Fluid
Description: Injection of 1 ml of processed amniotic fluid per 5 cm2 of wound area
Study NCT04438174 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Wound Treatment Regimen
Description: ointment-based dressing and non-ointment-based dressings
Study NCT04840680 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: This is a non-interventional study.
Study NCT05298137 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Passive Leg Raise
Description: A passive leg raise (PLR) is defined as raising a patient's legs to a 45-degree angle at the hip while supine.
Study NCT05034965 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hyaluronic acid filler injection
Description: quantitative surface electromyography before injection(baseline) and one week after injection
Study NCT05246137 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 Vaccine 40 ug/dose
Description: Intramuscular injection of 0,5 ml with 40 ug of recombinant PHH-1V
Study NCT05331885 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Suvratoxumab
Description: Monoclonal antibody
Study NCT05331885 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo contains only excipients
Study NCT05047757 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Test meal with 15N labeled favabean
Description: Ingestion of a 15N labeled test meal. Subjects are equipped with a nasoileal tube. 15N is followed in biological fluids (plasma, effluents, urines).
Study NCT05024955 — intervention group
Intervention type: PROCEDURE
Intervention: Discussion
Description: Attend a focus group
Study NCT05024955 — intervention group
Intervention type: OTHER
Intervention: Interview
Description: Attend interview
Study NCT05360056 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DexCom G6
Description: Wearable continuous glucose monitor
Study NCT04993404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jaktinib Hydrochloride Tablets
Description: A single oral dose of 100 mg Jaktinib Hydrochloride Tablets will be administered.
Study NCT06072885 — intervention group
Intervention type: OTHER
Intervention: Lung Ultrasound Scoring
Description: Pediatric Laparoscopic Surgery patients will be undergone Lung Ultrasound Scoring (LUS) at multiple times perioperatively. LUS is a pragmatic calculation reflecting lung aeration. Thorax is divided into 12 areas, and in every one of them LUS is applied to observe the lung condition. For that, if there are B-lines less than 4 in one area, it is scored as 1 point. For the areas containing more than 3 B-lines, it is scored as 2 points, and if there is any distortion on the pleural line, it is scored as 3 points. The areas with no B-lines is scored as 0 points. Considering these details, lungs with best conditions will reflect 0 points whereas the worst condition lungs will reflect 36 points. LUS will be performed after intubation, before extubation, and after 30th minute in the post anesthesia care unit
Study NCT04995146 — intervention group
Intervention type: OTHER
Intervention: Clinical stroke extended management pathway
Description: 1. Extracranial imaging~2. ECG in 2-7 days~3. DVT prophylaxis~4. Stroke educational material for patient and family Removal of Foley's catheter and start bladder management~5. Discharged on: Antithrombotic therapy OR Anticoagulation therapy▸ Antihypertensives ▸ Statins/cholesterol lower agent ▸ Antidiabetic agent~6. Fasting lipid profile, HbA1c~7. Holter monitor~8. Specialized workup for young stroke~9. PFO Study, MES Study~10. Referral to: ▸ Rehabilitation specialist ▸ Speech therapist ▸ Dietician ▸ Occupational therapist ▸ Medical team~11. Follow-up: CTA, CT angiography; HbA1c, glycated haemoglobin; MRA, MR angiography~12. Follow-up plan and 90 day mRS
Study NCT05491993 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Sky Medical™ Rapid Antigen Test
Description: Rapid Antigen Diagnostic Test device performance comparative to RT-PCR.
Study NCT04433650 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pictorial support in person-centred care for children (PicPecc)
Description: Phase A: The child has the protocol for methotrexate treatment, the healthcare professionals have one workshop that containing person-centred care, universal design, distress, symptom management and the digital reporting and communication tool.~Phase B: The child has everything in phase A. In addition, the child use the digital reporting and communication tool that has a thermometer (graded from zero (green) to ten (red)). The result of the assessment is visualized as a face (mimic and colour represents the intensity of the symptom and/or emotion (i.e., anxiety, appetite, fear/worries, how I´m feeling today, nausea, pain, sleep, and tiredness)). The digital reporting and communication tool has a body figure for location of pain, pictures for the type of pain, and an open question. There is an avatar and a gamification part, e.g., the child gets a pet after assessing the symptoms/emotions. The child reports in the app, and the child decides the frequency of assessments.
Study NCT04938258 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Case Management
Description: Participants will receive an intensive Case Management (CM) intervention conducted by a multidisciplinary team (Psychiatry, Social Work, Nursing) during 2 months. The intervention will encompass attending weekly or biweekly appointments with the CM team, the interviews will last approximately 30 minutes. This CM intervention will include referral to Hospital Clínic de Barcelona Addiction Outpatient Clinic and a personalised assessment of the medical, psychiatric and social situation of each individual by the CM team. An individualised care plan will be established and periodically reviewed by the multidisciplinary team in response to a better understanding of patient needs or to a change in patient health condition. The intervention will offer motivational interviewing psychotherapy to enhance motivation to reduce or to quit alcohol use, in crisis intervention, coordination of care, patient education and self-management support, and assistance to navigate in the healthcare system.
Study NCT05294744 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-acetylcysteine
Description: Day 1: 150 mg/kg in 250ml 5% glucose over 30min + 50mgr/kg in 500ml glucose over 4h + 100mgr/kg in 1000ml glucose over 16h intravenously.~Day 2-14: 100mgr/kg in 1000 ml glucose/24h intravenously. Day 15 until end of corticosteroid treatment: NAC 600mg orally every 24h.
Study NCT05294744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: Day 1: 150 mg/kg in 250ml 5% glucose over 30min + 50mgr/kg in 500ml glucose over 4h + 100mgr/kg in 1000ml glucose over 16h intravenously.~Day 2-14: 100mgr/kg in 1000 ml glucose/24h intravenously. Day 15 until end of corticosteroid treatment: NAC 600mg orally every 24h.
Study NCT06537115 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: exercise
Description: progressive resistance exercise